revolo biotherapeutics – Patient Worthy

MHRA Approves Two Phase 2 Clinical Trials of ‘1805 in Autoimmune Diseases in UK

Post author:Alyssa Stevens
Post published:February 9, 2022
Post category:Panuveitis Rheumatoid Arthritis Uveitis

According to a recent article, Revolo Biotherapeutics announced it has obtained approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for two Phase 2 clinical trials to analyze its…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More